A Prospective Trial on the Effect of Body Mass Index and Sex on Plasma Octreotide Levels in Patients Undergoing Long-Term Octreotide LAR Therapy
- 1 October 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 39 (7), 964-966
- https://doi.org/10.1097/mpa.0b013e3181db01a8
Abstract
Objectives: Octreotide long acting repeatable (LAR) is commonly used to control the symptoms of patients with functional neuroendocrine tumors. Unfortunately, most patients escape control over time and require higher LAR doses or more frequent rescue therapy to remain asymptomatic. Previous work has shown that body weight and monthly LAR dose will significantly affect circulating plasma octreotide levels in patients undergoing therapy. Methods: To determine if other parameters change circulating plasma octreotide levels, we prospectively studied 82 patients undergoing long-term LAR therapy. Results: Multivariate analysis demonstrated that the plasma octreotide levels decrease by approximately 3.4% for each unit of body mass index (BMI) increase (P = 0.03), adjusting for sex and monthly LAR dose. Plasma octreotide levels for females were approximately 47.6% higher than those for males (P = 0.045), adjusting for BMI and monthly LAR dose. Initial and subsequent octreotide LAR doses should take into consideration sex and BMI. Males are estimated to require 14.1-mg (SD, 7.25) higher monthly LAR doses than females with the same BMI. Conclusions: We have shown that plasma octreotide levels are affected by not only monthly LAR dose but also BMI and sex. We hope these observations will make choosing initial and subsequent octreotide LAR doses easier for physicians.Keywords
This publication has 8 references indexed in Scilit:
- Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid PatientsPancreas, 2008
- Effect of Octreotide LAR Dose and Weight on Octreotide Blood Levels in Patients With Neuroendocrine TumorsPancreas, 2005
- Octreotide LAR doses used in clinical practice: Results from an internet survey and a clinical practiceJournal of Clinical Oncology, 2004
- Octreotide LAR doses used in clinical practice: Results from an internet survey and a clinical practiceJournal of Clinical Oncology, 2004
- Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic systemAnnals of Oncology, 2004
- Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid SyndromeJournal of Clinical Oncology, 1999
- Consensus statement: Octreotide dose titration in secretory diarrheaDigestive Diseases and Sciences, 1995
- Mechanisms of action of long-acting analogs of somatostatinRegulatory Peptides, 1993